Prevention & lipids

AI-Identified Reasons for Nonescalation of Lipid-Lowering Therapy for Secondary Prevention

JAMA CardiolPublished retrospective cohort study

Authors' conclusion

Results of this study show that after using a state-of-the art LLM, nearly 9 in 10 ASCVD encounters with above-goal LDL-C level did not have patient LLT escalated, most often because of adverse effects, patient preference, preference for lifestyle changes, therapeutic inertia (eg, repeat laboratory tests), and near-goal LDL-C level. These findings highlight an avenue for personalizing system-level digital health interventions to help discover and minimize guideline-discordant care gaps in secondary prevention of ASCVD.

Study context

Population
Adults aged 18 to 90 years with 2 or more clinician-billed encounters for atherosclerotic cardiovascular disease (ASCVD) and with low-density lipoprotein cholesterol (LDL-C) level greater than or equal to 70 mg/dL at the most recent encounter, in a large, integrated health system in Northern Californiaunique patients with ASCVD-related encounters, 13,810 (49.1%) had above-goal LDL-C level
Participants
28,113 adults
Index test or model
Large language models (LLMs) against clinical annotations
Target condition
treat-to-target strategy use (LDL-C target documentation, LDL-C target value), LLT adjustment and reasons for LLT nonescalation documented in clinical notes

Performance

As reported in the abstract

Treat-to-target strategy use…

Micro-weighted F1 scores ranged from

0.80 to 0.98

Further findings

Characteristics of patients with above-goal LDL-C level

Patients with above-goal LDL-C level, of the 28 113 identified
13 810 (49.1%)
Mean (SD) age of those with above-goal LDL-C level
70.9 [11.4] years
Male, of those with above-goal LDL-C level
7904 male [57.2%]

Treat-to-target strategy (inference set)

Treat-to-target strategy identified, of all relevant notes
3756 (28.1%)
Targeting an LDL-C level less than 70 mg/dL
2280 [17.1%]
  • Inference set: 13 394 patients with above-goal LDL-C level and 13 354 relevant notes

Lipid-lowering therapy (LLT) nonescalation and reasons (inference set)

LLT not escalated, of all relevant notes
11 842 (88.7%)
Of those not escalated, containing at least 1 LLT nonescalation reason
4788 (40.4%)
Patient-reported adverse effects
1683 [12.6%]
LDL-C level close to goal
922 [6.9%]
Patient preference to avoid LLT
914 [6.8%]
Preference for lifestyle changes
811 [6.1%]
Deferral to repeat laboratory tests
617 [4.6%]

Original publication

AI-Identified Reasons for Nonescalation of Lipid-Lowering Therapy for Secondary Prevention. JAMA Cardiol. Published 7 November 2026. doi:10.1001/jamacardio.2026.5230

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.